Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alarm As Novartis Exits Antibiotics Space

Executive Summary

The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines."

Advertisement

Related Content

Pharma Q2 Results Preview: Johnson & Johnson And Novartis
Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure
Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups
ABAC Chief Calls For Better Antibiotic R&D Incentives In Europe
AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel